Your session is about to expire
← Back to Search
Mobile App Support for Blood Diseases
N/A
Recruiting
Led By Sung Won Choi, MD, MS
Research Sponsored by University of Michigan Rogel Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
An eligible patient is one who identifies the eligible caregiver as their primary caregiver (i.e., provides at least 50% of care needs)
An eligible patient is scheduled to undergo HCT
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at day 120 post-transplant
Awards & highlights
Study Summary
This trial will test how well a mobile phone app improves the quality of life for caregivers and patients during hematopoietic cell transplantation.
Who is the study for?
This trial is for caregivers aged 18+ and patients aged 5+ who are undergoing hematopoietic cell transplantation (HCT). Caregivers must provide most care, be comfortable with English, and have a smartphone. Patients need to meet HCT eligibility at U-M or Oregon Health & Sciences University.Check my eligibility
What is being tested?
The study tests the Roadmap 2.0 app's impact on health-related quality of life during HCT. Participants will use the app along with a wearable activity sensor and complete surveys; some may engage in positive activities through the system.See study design
What are the potential side effects?
Since this trial involves an information system and not medication, traditional side effects are not expected. However, participants might experience stress or discomfort from constant monitoring or using new technology.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My primary caregiver provides most of my care needs.
Select...
I am scheduled for a stem cell transplant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at day 120 post-transplant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 120 post-transplant
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Caregiver health-related quality of life (HRQOL) assessed by the PROMIS Global Health scale.
Secondary outcome measures
Caregiver health-related quality of life (HRQOL) assessed by PROMIS Profile 29
Other outcome measures
Caregiver health-related quality of life (HRQOL) assessed by PROMIS Profile 29+2 (exploratory)
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Roadmap 2.0 with Positive ActivitiesExperimental Treatment3 Interventions
Roadmap 2.0 mobile app (patients), Roadmap 2.0 with mobile Positive Activities app (caregivers) + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
Includes caregivers of adult patients and caregivers of pediatric patients
Group II: Roadmap 2.0Active Control3 Interventions
Roadmap 2.0 mobile app + wearable sensor to track activity and sleep + usual care (informational or educational resources provided through verbal communication or written hand-out materials).
Includes caregivers of adult patients and caregivers of pediatric patients
Find a Location
Who is running the clinical trial?
Department of Health and Human ServicesFED
226 Previous Clinical Trials
928,285 Total Patients Enrolled
University of Michigan Rogel Cancer CenterLead Sponsor
293 Previous Clinical Trials
23,433 Total Patients Enrolled
Sung Won Choi, MD, MSPrincipal InvestigatorUniversity of Michigan Rogel Cancer Center
4 Previous Clinical Trials
2,697 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older and a caregiver.My primary caregiver provides most of my care needs.I am 5 years old or older.I am scheduled for a stem cell transplant.
Research Study Groups:
This trial has the following groups:- Group 1: Roadmap 2.0
- Group 2: Roadmap 2.0 with Positive Activities
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research endeavor currently accept new participants?
"According to the data available on clinicaltrials.gov, this trial is actively recruiting patients. It was originally posted on September 8th 2020 and has recently been revised as of December 16th 2021."
Answered by AI
Are elderly individuals above 85 years of age accepted into this medical trial?
"The requirements for this clinical trial stipulate that potential participants must have ages between 5 and 75. For those younger than 5 or older than 65, there are 30 trials available to minors and 42 geared towards seniors respectively."
Answered by AI
Is it possible for me to participate in this experiment?
"To gain admission to this medical experiment, individuals need to have a hematologic condition and must be aged between 5 and 75. This trial is expected to recruit 664 participants total."
Answered by AI
How many individuals are currently enrolled in this medical experiment?
"That is correct. According to information posted on clinicaltrials.gov, the trial that was first published in September of 2020 is actively recruiting participants and requires 664 individuals across 2 different sites."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger